Compounds > hydroxychloroquine

hydroxychloroquine and dabrafenib

hydroxychloroquine has been researched along with dabrafenib in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Aleman, TS; Amaravadi, RK; Bowman, S; Edelstein, ID; Gangadhar, TC; Huang, A; Kim, BJ; Mitnick, S; Nichols, CW; Nti, AA; Sandhu, HS; Schuchter, LM; Serrano, LW; Song, D; Uyhazi, KE; Zhou, EJ1
Aleman, TS; Amaravadi, RK; Ansstas, G; Carberry, M; Chandra, S; Frey, N; Giles, L; Gimotty, PA; Groisberg, R; Hernandez-Aya, LF; Huang, AC; Karakousis, GC; Kim, BJ; Kossenkov, A; Linette, GP; Mehnert, JM; Mick, R; Mitchell, TC; Mitnick, S; Schuchter, LM; Silk, AW; Sosman, JA1
Awada, G; Fasolino, G; Kruse, V; Neyns, B; Schwarze, JK; Tijtgat, J1

Trials

3 trial(s) available for hydroxychloroquine and dabrafenib

ArticleYear
FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.
    Retina (Philadelphia, Pa.), 2019, Volume: 39, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Hydroxychloroquine; Imidazoles; Macula Lutea; Male; MAP Kinase Kinase 1; Melanoma; Middle Aged; Oximes; Photoreceptor Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Retinal Diseases; Retinal Pigment Epithelium

2019
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 03-15, Volume: 28, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Humans; Hydroxychloroquine; Imidazoles; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Oximes; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones

2022
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
    Melanoma research, 2022, 06-01, Volume: 32, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydroxychloroquine; Imidazoles; Immune Checkpoint Inhibitors; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms

2022